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Abstract: Rationale: ฀-calcitonin gene related peptide (฀CGRP), one of the strongest vasodilators, is
cardioprotective in hypertension by reducing the elevated blood pressure (BP). Objective: However, we
hypothesize that endogenous, physical activity-induced ฀CGRP has BP-independent cardioprotective ef-
fects in chronic hypertension. MMethods and Results: Chronically hypertensive (one-kidney-one-clip
surgery) WT and ฀CGRP-/- sedentary or voluntary wheel running mice were treated with vehicle, ฀C-
GRP, or the ฀CGRP receptor antagonist CGRP8-37. Cardiac function and myocardial phenotype were
evaluated echocardiographically and by molecular, cellular and histological analysis, respectively. BP was
similar among all hypertensive experimental groups. Endogenous ฀CGRP limited pathological remodel-
ing and heart failure in sedentary, chronically hypertensive WT mice. In these mice, voluntary wheel
running significantly improved myocardial phenotype and function, which was abolished by CGRP8-37
treatment. In ฀CGRP-/- mice, ฀CGRP treatment, in contrast to voluntary wheel running, improved my-
ocardial phenotype and function. Specific inhibition of proliferation and myofibroblast differentiation of
primary, murine cardiac fibroblasts by ฀CGRP suggests involvement of these cells in ฀CGRP-dependent
blunting of pathological cardiac remodeling. Conclusions: Endogenous, physical activity-induced ฀CGRP
has BP-independent cardioprotective effects and is crucial for maintaining cardiac function in chronic
hypertension. Consequently, inhibiting endogenous ฀CGRP signaling, as currently approved for migraine
prophylaxis, could endanger hypertensive patients.
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Rationale: α-calcitonin gene related peptide (αCGRP), one of the strongest vasodilators, is cardioprotective 
in hypertension by reducing the elevated blood pressure (BP).  
 
Objective: However, we hypothesize that endogenous, physical activity-induced αCGRP has BP-
independent cardioprotective effects in chronic hypertension.  
 
Methods and Results: Chronically hypertensive (one-kidney-one-clip surgery) WT and αCGRP-/- 
sedentary or voluntary wheel running mice were treated with vehicle, αCGRP, or the αCGRP receptor 
antagonist CGRP8-37. Cardiac function and myocardial phenotype were evaluated echocardiographically 
and by molecular, cellular and histological analysis, respectively. BP was similar among all hypertensive 
experimental groups. Endogenous αCGRP limited pathological remodeling and heart failure in sedentary, 
chronically hypertensive WT mice. In these mice, voluntary wheel running significantly improved 
myocardial phenotype and function, which was abolished by CGRP8-37 treatment. In αCGRP-/- mice, 
αCGRP treatment, in contrast to voluntary wheel running, improved myocardial phenotype and function. 
Specific inhibition of proliferation and myofibroblast differentiation of primary, murine cardiac fibroblasts 
by αCGRP suggests involvement of these cells in αCGRP-dependent blunting of pathological cardiac 
remodeling. 
 
Conclusions: Endogenous, physical activity-induced αCGRP has BP-independent cardioprotective effects 
and is crucial for maintaining cardiac function in chronic hypertension. Consequently, inhibiting 
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Nonstandard Abbreviations and Acronyms: 
 
1K1C   one-kidney-one-clip 
2',5'-DDA 2',5'-Dideoxyadenosine 
AngII   angiotensin-II 
AR   aortic rupture 
BP  blood pressure 
CALCRL  calcitonin receptor-like receptor 
Calsq1  calsequestrin-1 
CF  cardiac fibroblasts 
CI   confidence interval 
Col1a1  collagen type-1 α1 
Col3a1  collagen type-3 α1 
CSA   cross-sectional area 
DCP  dilated cardiac phenotype  
ddPCR   droplet digital PCR 
EF   ejection fraction 
EPAC1  exchange protein directly activated by cAMP 1 
FS   fractional shortening 
H&E   hematoxylin and eosin  
HF   heart failure 
HW/TL  heart weight to tibia length ratio 
KF   kidney failure 
LV   left ventricular 
Myh   myosin heavy chain 
Nppa  atrial natriuretic peptide 
Nppb  brain natriuretic peptide 
PRD   presumed cardiac rhythm disturbance 
RAMP1  receptor activity modifying protein-1 
RWT   relative wall thickness 
SERCA2 sarcoplasmic reticulum Ca2+ ATPase-2 
VG   van Gieson’s 
WGA   wheat germ agglutinin 
αCGRP  α-calcitonin gene related peptide 






Chronic hypertension affects more than one billion people worldwide and is the major cause for 
cardiovascular mortality and morbidity, and the leading global risk factor for heart failure (HF).1,2 
Continuously elevated blood pressure (BP) stimulates cardiomyocytes to increase sarcomere gene 
transcription resulting in cellular hypertrophy, and cardiac fibroblasts to differentiate into collagen secreting 
myofibroblasts causing interstitial fibrosis, impairing contractile function and finally resulting in clinical 
HF.3,4 Consequently, reduction of pathologically increased BP is currently the most important therapeutic 
measure, especially if the cause is unknown, as in chronic primary hypertension. However, a significant 
percentage of hypertensive patients is unresponsive to anti-hypertensive therapy.5 Evidence indicates that 
hypertension-induced pathological ventricular remodeling can be manipulated despite persistent pressure 
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hypertrophy and limiting fibrosis might preserve cardiac function and impede progression to HF, in cases 
where the BP cannot be controlled sufficiently.3,4,7 
 
In contrast to hypertension, exercise also induces cardiac hypertrophy but does not impair heart 
function or lead to HF. Previous hypotheses suggest that the chronicity (hypertension as continuous vs 
exercise as intermittent) of a stimulus determines the kind of cardiac hypertrophy. However, a recent study 
has shown that the nature of the stimulus is important for the hypertrophy phenotype.8 One mechanism 
behind this observation is systemic α-calcitonin gene related peptide (αCGRP) signaling, since exercise 
induces a pathological cardiac phenotype, similar to that seen in hypertension, in αCGRP-deficient mice.9 
In line with this, several independent studies showed that plasma αCGRP concentrations increase in tight 
correlation to lactate during exercise.10-14 In working muscles, lactate and low pH activate the 
metaboreceptor transient receptor potential vanilloid in group III afferent (A-δ) nerves which mediate the 
well-established exercise pressor reflex15 and cause neuronal exocytosis of αCGRP.10,16-18 αCGRP interacts 
with the receptor formed of calcitonin receptor-like receptor (CALCRL), receptor activity modifying 
protein-1 (RAMP1) and receptor component protein. It activates cAMP-dependent signaling pathways that 
protect cardiomyocytes from stress-induced apoptosis19, and induce physiological cardiomyocyte growth 
and positive inotropy.9,20,21 Moreover, exercise antagonizes hypertension-induced pathological 
cardiomyocyte growth and reduces myocardial fibrosis22, and is therefore recommended in chronic 
hypertensive patients with symptomatic HF.23 Intravenous administration of αCGRP delays the onset of 
myocardial ischemia upon exercise in patients with stable angina pectoris24 and improves cardiac function 
in patients with congestive HF.25,26 A recent study demonstrated that systemic administration of a long-
lasting αCGRP-analogue reduces the increased BP and consequently improves cardiac function in murine 
models of hypertension and HF.27  
 
Here, we tested our hypothesis that exercise-induced, endogenous αCGRP suppresses 
hypertension-induced pathological cardiac remodeling in the one-kidney-one-clip (1K1C) murine model of 
chronic hypertension.28,29 Voluntary cage wheel running was chosen as exercise intervention since it avoids 
physical and psychological stress caused by forced exercise.30 Myocardial effects of exercise-induced 
αCGRP agonism in chronic hypertension were investigated by assessing the cardiac function 
echocardiographically, and pathological ventricular remodeling by analyzing the cardiac gene expression 
signature, cardiomyocyte hypertrophy and interstitial fibrosis. We found that endogenous αCGRP is crucial 
for the beneficial cardiac effects of exercise in chronic hypertension without reducing the associated 
elevated BP. Of note, blocking the basal αCGRP signaling with a CGRP receptor antagonist worsened the 
myocardial phenotype and function in sedentary WT mice. Thus, as also suggested by others27, we consider 
that activating the αCGRP pathway could have therapeutic potential in chronic hypertension. Further, our 
study reveals severely impaired left ventricular (LV) function as a potentially life-threatening adverse effect 
of long-term endogenous αCGRP inhibition in the setting of chronic hypertension. The FDA has recently 
approved αCGRP antagonists for migraine prophylaxis.31,32  Therefore, our data are important as we present 






















































Male C57BL/6J WT and αCGRP deficient (αCGRP-/-, characterized previously33) mice with the same 
genetic background, and normal calcitonin gene expression and baseline BP33, aged 14 to 16 weeks were 
used. All experiments were conducted in accordance with institutional and governmental guidelines 
(Supplemental Methods) and approved by the Cantonal Veterinary Department, Zürich, Switzerland.  
 
1K1C hypertension model. 
Hypertension was induced by clamping the left renal artery with an U-shaped stainless steel clip and 
removing the right kidney as described28,29 (Supplemental Methods).  
 
Exercise interventions and treatments. 
To ensure chronic hypertension29, mice were assigned to the experimental groups 8 weeks after 1K1C 
micro-surgery by single housing them with or without access to computerized cage wheel running for 
additional 4 weeks (Supplemental Methods). Simultaneously, mice were treated with vehicle (10% 
dimethyl-sulfoxide in PBS), αCGRP (4 nM/h) or CGRP8-37 (80 nM/h) using micro-osmotic pumps that 
were replaced once after 14 days to cover the entire 4 weeks of the treatment period. Initially, the stability 
of αCGRP and CGRP8-37 in micro-osmotic pumps at 37°C for 14 days (Supplemental Methods, Online 
Figure I) and the increase in plasma αCGRP concentrations upon αCGRP peptide treatment was verified 
(Online Table I).   
 
Echocardiography and LV phenotype classification. 
Assessment of cardiac dimensions and systolic LV function in M-mode images of the LV in a parasternal 
short axis view were carried out using a Vevo 2100, Visualsonics system and the data were analyzed using 
Vevo 2100 software (Supplemental Methods). To classify the myocardial phenotypes observed, the upper 
95% confidence interval (CI) of the mean of relative wall thickness (RWT) and heart weight to tibia length 
ratio (HW/TL) of sham-operated WT and αCGRP-/- mice were determined (Online Table II). The RWT 
and HW/TL of each individual 1K1C-operated mouse was then determined, resulting in assignment to one 
of the five myocardial LV structural patterns (Supplemental Methods, Online Figure II). This classification 
scheme was modified (to become mouse specific) from that described in previous studies4 and is in 
accordance with the American Society of Echocardiography’s recommendations on defining LV 
myocardial phenotypes. As none of the mice with chronic hypertension induced by 1K1C in our study 
showed ‘normal’ and ‘concentric remodeling’, and only two mice showed ‘eccentric hypertrophy’, only the 
data from animals exhibiting ‘concentric hypertrophy’ or ‘dilated cardiac phenotype’ (i.e. excluding the 
two mice with ‘eccentric hypertrophy’) are shown in the results.  
 
BP measurements. 
BP measurements were performed by femoral artery catheterization as described9 (Supplemental Methods).  
 
Droplet digital PCR (ddPCR) analysis. 
Total RNA isolated from heart tissues and cardiac fibroblasts (CF) were reverse transcribed into cDNA and 
ddPCR was performed as described9 (Supplemental Methods). Sequence specific Taqman PCR gene 
expression probes (target species: mouse) used and their Assay ID are listed in supplemental methods.  
 
Histology. 
Heart tissue sections were stained with hematoxylin and eosin (H&E) for histopathology and morphometry 
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wheat germ agglutinin for delineating plasma membranes and quantifying cardiomyocyte cross-sectional 
area,  and DyLightTM649-conjugated GSL isolectin-B4 for measurement of capillary to myocyte ratio. 
Images were acquired using an Axio Imager.Z2. microscope equipped with a digital camera and the 
AxioVision Rel. 4.8 software, and analyzed using MCID Analysis software (Supplemental Methods, Online 
Figures III-V). 
 
Mice that either were euthanized due to signs of kidney failure (KF) or died suddenly without signs of 




Total collagen and protein contents of the heart sections, and cultured CF were spectrophotometrically 
quantified using Sirius red/Fast green Collagen Staining kit as described9 (Supplemental Methods).  
 
Blood plasma analysis. 
Plasma αCGRP, angiotensin-II (AngII), renin-1, triglyceride and free fatty acid concentrations were 
quantified using mouse-specific EIA or ELISA kits (Supplemental Methods). 
 
Cell culture experiments. 
Adult murine CF were isolated and cultured in DMEM/F-12 supplemented with 10% FBS and 1% 
penicillin-streptomycin as described 34 with some modifications (Supplemental Methods). Cell proliferation 
was quantified by measuring BrdU incorporation during DNA synthesis, and cAMP and exchange protein 
directly activated by cAMP 1 (EPAC1) concentrations in cell lysates were determined using a cAMP and 
EPAC1 ELISA Kits and normalized for cellular total protein according to the manufacturer’s instructions 
(Supplemental Methods). Immunofluorescence staining of α-smooth muscle actin (αSMA) and collagen 
was performed with appropriate negative controls (secondary antibody only) as described 39 with 
modifications (Supplemental Methods). Images were captured using an Axio Imager.Z2. microscope 
equipped with a digital camera and associated AxioVision Rel.4.8 software. 
 
Statistics. 
Data were analyzed using GraphPad Prism software version 8.0, and tested for normality by Shapiro-Wilk 
test and homogeneity of variances.  When parametric assumptions were met, an unpaired Student’s t-test 
was used for comparing two independent groups and one-way ANOVA followed by Bonferroni post hoc 
test was used for comparing multiple groups. Student’s t-test was used only when the specific research 
question involved comparing two independent groups (with parametric assumptions met). When parametric 
assumptions were not met, Kruskal-Wallis followed by Dunn’s multiple comparison test was used. While 
we corrected for multiple testing in post-hoc comparisons, we did not correct across tests. The survival data 
were plotted using the Kaplan-Meier method and the comparison was performed with the Mantel-Cox test. 






Since 1K1C surgery results in stable hypertension by the 4th week28 after surgery and chronic 
hypertension is established at the latest by the 8th week29, all WT and αCGRP-/- mice that underwent 1K1C 
surgery were single housed for 8 weeks under standard conditions. Mice were then housed with or without 
access to voluntary cage wheel running and treated simultaneously with vehicle, αCGRP, or αCGRP 
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αCGRP deficiency impairs survival in chronic hypertension. 
 
Following 1K1C surgery, αCGRP-/- mice exhibited significantly reduced survival compared with 
WT mice. Kidney failure (KF) and aortic rupture (AR) occurred in 9% and 4% of WT mice after 1K1C 
surgery, respectively and 87% WT mice survived up to the study end point. In contrast, KF, AR and dilated 
cardiac failure were observed in 31%, 17% and 6% of αCGRP-/- mice, respectively and 38% of αCGRP-/- 
mice survived up to the study end point. In 8% of 1K1C-operated αCGRP-/- mice, the cause of death could 
not be determined by the post-mortem analysis and therefore were presumed to be resulting from cardiac 
rhythm disturbances (Figure 1).  
 
αCGRP deficiency or αCGRP antagonism increases the occurrence of dilated cardiac phenotype in chronic 
hypertension. 
 
After 4 weeks of treatment, the LV myocardial structural pattern of each individual 1K1C-operated 
mouse was defined according to the classification scheme outlined in supplemental methods and Online 
Figure II. All vehicle- and αCGRP-treated WT mice in both sedentary and voluntarily running groups had 
increased RWT and HW/TL (Figure 2A, B, blue dots), and were classified as exhibiting a concentric 
hypertrophy phenotype (Figure 2C). In contrast, only 66.66% of antagonist-treated WT mice in sedentary 
and 71.43% of antagonist-treated WT mice in voluntarily running groups had increased RWT and HW/TL 
(Figure 2A, B, blue dots), and were classified as exhibiting a concentric hypertrophy phenotype (Figure 
2C). The remaining 33.33% of antagonist-treated WT mice in sedentary and 28.57% of antagonist-treated 
WT mice in voluntarily running groups had decreased RWT and increased HW/TL  (Figure 2A, B, red 
dots), and were classified as exhibiting a dilated cardiac phenotype (Figure 2C). In line with this, 66.67% 
of sedentary, vehicle-treated αCGRP-/- mice, 66.67% of voluntarily running, vehicle-treated αCGRP-/- 
mice, 88.89% of sedentary, αCGRP-treated αCGRP-/- mice, and 77.78% of voluntarily running, αCGRP-
treated αCGRP-/- mice showed increased RWT and HW/TL (Figure 2A, B, blue dots), and were classified 
as exhibiting a concentric hypertrophy phenotype (Figure 2C). The remaining 33.33% of sedentary, vehicle-
treated αCGRP-/- mice, 33.33% of voluntarily running, vehicle-treated αCGRP-/- mice, 11.11% of 
sedentary, αCGRP-treated αCGRP-/- mice, and 22.22% of voluntarily running, αCGRP-treated αCGRP-/- 
mice showed decreased RWT and increased HW/TL (Figure 2A, B, red dots), and were therefore classified 
as exhibiting a dilated cardiac phenotype (Figure 2C).  
 
At the end of the treatment period, all 1K1C-operated mice were, in general, similarly hypertensive. 
Only in some mice with dilated cardiac phenotype, systemic BP was not higher than that measured in sham 
animals (Figure 2D, Online Table III), possibly indicating cardiac decompensation and impending failure.   
 
αCGRP deficiency impairs voluntary wheel running activity and exacerbates pathological cardiomyocyte 
hypertrophy in chronic hypertension. 
 
Compared with vehicle-treated hypertensive WT mice, vehicle-treated hypertensive αCGRP-/- 
mice exhibited significantly reduced cage wheel running. Treatment with αCGRP significantly increased 
cage wheel running in hypertensive WT and αCGRP-/- mice (Figure 3A- C). Sham-operated WT and 
αCGRP-/- mice showed similar levels of voluntary wheel running activity (Online Figure VI), thereby 
proving that global αCGRP deficiency adversely affected wheel running activity only in the setting of 
chronic hypertension. Directly after 7 minutes of continuous voluntary running, plasma αCGRP 
concentrations were significantly increased in naive, normotensive (+40%) and vehicle-treated 
hypertensive WT (+25%) mice compared with their respective sedentary controls (Figure 3D, E). 
 
Voluntarily running, vehicle-treated and sedentary, αCGRP-treated hypertensive WT mice showed 
significantly decreased cardiomyocyte hypertrophy compared with sedentary, vehicle-treated hypertensive 
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in voluntarily running hypertensive WT mice. Similarly, cardiomyocyte hypertrophy was significantly 
increased in sedentary, vehicle-treated hypertensive αCGRP-/- compared with sedentary, vehicle-treated 
hypertensive WT mice. This suggests that impairment of even basal systemic αCGRP signaling increases 
cardiomyocyte hypertrophy. Accordingly, treatment with αCGRP significantly suppressed cardiomyocyte 
hypertrophy in sedentary, and voluntarily running hypertensive αCGRP-/- mice (Figure 4). Morphometry 
of cardiac vessels showed that αCGRP deficiency, agonism or antagonism did not significantly alter 
capillary to myocyte ratio (Online Figure VIIa). Arteriolar or arterial structure in chronic hypertensive mice 
were changed slightly and unsystematically in a few groups only (Online Figure VIIb-j). Thus, angiogenesis 
or other changes of the cardiac vasculature may not have contributed to the observed protective effect of 
αCGRP. 
 
Physical activity-induced endogenous αCGRP signaling improves ejection fraction (EF) and fractional 
shortening (FS) in chronic hypertension. 
 
Echocardiography revealed significantly improved EF and FS in voluntarily running, vehicle-
treated and sedentary, αCGRP-treated hypertensive WT mice compared with sedentary, vehicle-treated 
hypertensive WT mice. Antagonist (CGRP8-37)-treated sedentary mice showed lower EF and FS compared 
with their vehicle-treated hypertensive WT counterparts (Figure 5). CGRP8-37 treatment significantly and 
completely abolished the positive effects of voluntary running on cardiac function in voluntarily running 
hypertensive WT mice. Sedentary, vehicle-treated hypertensive αCGRP-/- mice showed significantly 
decreased EF and FS compared with sedentary, vehicle-treated hypertensive WT mice. Compared with 
vehicle treatment, αCGRP treatment significantly increased EF and FS in both sedentary and voluntarily 
running hypertensive αCGRP-/- mice. Note that combining αCGRP treatment with exercise, compared with 
sole αCGRP treatment, did not further improve EF and FS in hypertensive αCGRP-/- mice. Voluntarily 
running, vehicle-treated hypertensive αCGRP-/- mice had, only by trend, a slightly increased EF and FS 
compared with sedentary, vehicle-treated hypertensive αCGRP-/- mice. Cardiac function was more 
impaired in the dilated hearts compared with the concentric phenotype in the respective groups (Figure 5). 
The complete echocardiography data are given in Online Table VI.    
 
Physical activity-induced endogenous αCGRP signaling suppresses hypertension-induced myocardial fetal 
gene expression signature. 
 
The adult heart responds to hypertension by fetal gene reinduction including isoform switching of 
sarcomeric myosin heavy chain (Myh, decreased Myh6 and increased Myh7 expression), upregulation of 
atrial (Nppa) and brain (Nppb) natriuretic peptides, and downregulation of sarcoplasmic reticulum Ca2+ 
ATPase-2 (SERCA2).36 Compared with sedentary, vehicle-treated hypertensive WT mice, voluntarily 
running, vehicle-treated and sedentary, αCGRP-treated hypertensive WT mice exhibited significantly 
higher Myh6 and SERCA2, and lower Myh7, Nppa, and Nppb expression (Figure 6). Antagonist (CGRP8-
37) treatment significantly and completely suppressed the positive effects of exercise on myocardial fetal 
gene expression signature in voluntarily running hypertensive WT mice. Sedentary, vehicle-treated 
hypertensive αCGRP-/- mice showed significantly decreased Myh6 and SERCA2, and upregulated Myh7, 
Nppa, and Nppb expression compared with sedentary, vehicle-treated hypertensive WT mice. This suggests 
that impairment of even basal systemic αCGRP signaling worsens the cardiac fetal gene expression 
signature in chronic hypertension. Treatment with αCGRP significantly upregulated Myh6 and SERCA2, 
and downregulated Myh7, Nppa, and Nppb expression in sedentary, and voluntarily running hypertensive 
αCGRP-/- mice. Voluntarily running, vehicle-treated hypertensive αCGRP-/- mice showed no significant 
expression difference in Myh6, SERCA2, Myh7, and Nppb compared with sedentary, vehicle-treated 
hypertensive αCGRP-/- mice. In CGRP8-37-treated hypertensive WT, and vehicle- or αCGRP-treated 
hypertensive αCGRP-/- mice in both sedentary and voluntarily running groups, fetal Myh isoform switching 
was prominent and changes in the expression of Nppa, Nppb and SERCA2 were more adversely affected 
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Taken together, these data indicate that in chronic hypertension, global αCGRP deficiency or 
αCGRP receptor antagonism aggravates the fetal gene expression signature of the pathological cardiac 
hypertrophy in the absence of exercise, and furthermore, suppresses the positive effects of exercise. 
Conversely, the expression signature of pathological cardiac hypertrophy can be suppressed by either 
exercise or αCGRP treatment.    
 
Physical activity-induced endogenous αCGRP signaling suppresses hypertension-induced myocardial 
fibrosis and myofibroblast differentiation. 
 
Interstitial fibrosis that occurs in hypertension is a key feature distinguishing physiological from 
pathological myocardial remodeling.37 Interstitial fibrosis and cardiac collagen level were significantly 
decreased in voluntarily running, vehicle-treated, and sedentary, αCGRP-treated hypertensive WT mice 
compared with sedentary, vehicle-treated hypertensive WT mice. In contrast, antagonist (CGRP8-37) 
treatment significantly and completely abolished the beneficial effects of exercise on interstitial fibrosis 
and collagen level in voluntarily running hypertensive WT mice. Sedentary, vehicle-treated hypertensive 
αCGRP-/- mice showed notably increased interstitial fibrosis and collagen level compared with sedentary, 
vehicle-treated hypertensive WT mice. This suggests that impairment of even basal systemic αCGRP 
signaling increases hypertension-induced cardiac fibrosis. Accordingly, αCGRP treatment notably 
suppressed interstitial collagen deposition in sedentary, and voluntarily running hypertensive αCGRP-/- 
mice. Interstitial fibrosis and collagen level were higher in dilated hearts compared with the concentric 
phenotype in the respective groups (Figure 7).  
 
Cardiac fibroblasts (CF) are the major cell type secreting collagen during hypertension.3 We tested 
in vitro if adult murine CF respond specifically to αCGRP treatment. Treatment with αCGRP significantly 
increased cAMP production in CF (Figure 8A, Online Figure VIII). To elucidate αCGRP’s direct effects 
on collagen synthesis by CF, we stimulated CF with the potent pro-fibrotic hypertensive peptide AngII in 
the absence or presence of αCGRP. Expression of collagen (Figure 8B- D), and αSMA (encoded by Acta2, 
Online Figure IXa, b), the molecular markers of pro-fibrotic myofibroblast differentiation, were highly 
increased upon AngII treatment, in accordance with previous findings.3 In addition, proliferation of CF, 
another profibrotic process38, was also significantly stimulated by AngII (Figure 8E). These pro-fibrotic 
effects of AngII, i.e. the induction of collagen (Figure 8B- D) and αSMA (Online Figure IXa, b) expression, 
and cell proliferation (Figure 8E) were significantly suppressed in CF when these cells were treated with a 
combination of AngII and αCGRP, which in turn was reversed by CGRP8-37 treatment.  
 
AngII induces profibrotic gene expression and myofibroblast transformation by transcriptional 
downregulation of EPAC1 in CF. Accordingly, it is shown that upregulating EPAC1 expression by 
enhancing cyclic AMP release can inhibit AngII-induced profibrotic transformation of CF.39,40 AngII 
downregulated EPAC1 expression in CF, thereby confirming previous findings.39,40 Combining AngII with 
αCGRP, the latter being a cAMP inducer41 (Figure 8A), significantly upregulated EPAC1, and this effect 
was blocked by the cAMP synthesis inhibitor 2',5’-Dideoxyadenosine (2’5-DDA40, Figure 8F, Online 
Figure IXc). Moreover, treatment with 2’5-DDA, and the EPAC1 specific inhibitor CE3F442 abolished 
αCGRP’s beneficial effects on AngII-induced collagen (Figure 8B-D) and αSMA (Online Figure IX) 
synthesis, and cell proliferation (Figure 8E). 
 
This combination of in vivo and in vitro data clearly suggests that hypertension-induced cardiac 
fibrosis is aggravated in the absence of αCGRP or by the inhibition of systemic αCGRP signaling. At the 
cellular level, the cAMP effector EPAC1 regulates the direct antifibrotic effects of αCGRP in CF. In vivo, 
αCGRP treatment inhibits hypertension-induced cardiac fibrosis, a key feature of pathological heart 
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effect in WT mice could be inhibited by CGRP8-37, thereby suggesting that inhibition of cardiac fibrosis 
by exercise is αCGRP-dependent.  
 
αCGRP did not significantly alter plasma AngII concentrations (Online Figure Xa), thereby 
excluding a direct modulatory effect of αCGRP on circulating AngII concentration in hypertensive mice. 
However, αCGRP deficiency slightly increased plasma renin-1 concentrations (Online Figure Xb). This 
finding of unaltered plasma AngII despite increased plasma renin-1 concentrations, and the complex 
interaction of αCGRP with renin-angiotensin-aldosterone system during hypertension warrants further 
investigation.  
 
Although exercise-induced or injected αCGRP promotes lipolysis in normotensive rats.43, αCGRP 
did not alter plasma free fatty acid and triglyceride concentrations in our setting (Online Figure X), thereby 




DISCUSSION    
 
Modern antihypertensive therapy includes suggestions for lifestyle changes, of which increased 
physical activity is a centrally important cornerstone.44 Exercise improves cardiac function even when 
hypertension is not significantly reversed.45 A recent multicenter study showed that little regular physical 
activity such as walking for about 30 min per day, is the most important independent factor maintaining 
cardiovascular health.46 Based on the findings from HF-ACTION trial that investigated the effects of 
exercise in about 2300 human subjects with HF23, exercise has been recommended as part of cardiac 
rehabilitation even when EF is reduced.37 It is not completely understood yet why exercise is beneficial but 
our study might provide some explanation to help answer this question. 
 
The αCGRP receptors are constitutively present in the myocardium9,47, and αCGRP agonism or 
antagonism did not alter their cardiac expression in the present study (Online Figure VIII). Previous studies 
showed that exercise prevents fetal gene reactivation and fibrosis in the heart, thereby keeping the heart in 
an adaptive phase during persistent pressure load.22 Accordingly, we found suppressed fetal gene 
reactivation and myocardial fibrosis together with a better heart function (Figure 5) in voluntarily running, 
vehicle-treated hypertensive WT mice compared with their sedentary counterparts. These cardioprotective 
effects of exercise were negated by treatment with the αCGRP receptor antagonist CGRP8-37. CGRP8-37 
treatment worsened pathological myocardial remodeling also in sedentary hypertensive WT mice because 
these mice without access to a running wheel still had basal physical activity. Basal plasma αCGRP 
concentrations may result from an overspill of αCGRP from sensory neurons.41 After induction of 
hypertension, αCGRP-/- mice had considerably more cardiovascular events and were affected with a dilated 
cardiac phenotype compared with hypertensive WT mice (Figure 1B). Accordingly, hypertensive αCGRP-
/- mice (sedentary, vehicle-treated) had signs of severe pathological cardiac remodeling and worse cardiac 
function compared with their WT counterparts. Moreover, the dilated cardiac phenotype with severely 
impaired cardiac function and enhanced fibrosis, seen in all hypertensive groups of αCGRP-/- mice, 
occurred in hypertensive WT mice only when WT were treated with CGRP8-37. Thus, impaired αCGRP 
signaling may worsen pathological cardiac remodeling and induce the dilated cardiac phenotype with 
reduced LV function and failure. Other αCGRP-/- mice with combined deletion of αCGRP and calcitonin, 
and altered baseline cardiovascular variables apparently due to calcitonin deficiency41 exhibit reduced 
survival and cardiac function upon pressure stress.48,49 Importantly, our study shows that hypertensive 
αCGRP-/- mice with unaltered calcitonin expression33 have reduced survival, and failed to improve cardiac 
fetal gene expression profile, fibrosis and cardiac function by voluntary running alone. In contrast, αCGRP 
treatment resulted in considerable reduction of the cardiac fetal gene expression reactivation and myocardial 
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improvement from simultaneous exercise. Improvement of the myocardial phenotype and cardiac function 
induced by voluntary running in WT mice is due to transient exercise-induced increase in plasma αCGRP 
concentration (Figure 3D, E), since this was abolished after systemic CGRP8-37 treatment. Importantly, 
the αCGRP treatment used in this study did not alter the degree of elevated BP in any of the experimental 
groups (Figure 2D), thereby suggesting that the observed effects are BP-independent. The latter notion is 
important because, to the best of our knowledge, the cardioprotective effects shown in previous studies 
employing αCGRP treatment during systemic hypertension were accompanied by reduction of elevated 
BP.27,50,51 Further, our data of  unaltered structure of cardiac vasculature in response to αCGRP treatment 
and αCGRP deficiency or antagonism in hypertension suggest that improvements of the cardiac 
microcirculation may not have contributed to the observed protective effects of αCGRP. The in vitro 
observation that αCGRP activates the cAMP effector EPAC1 to suppress myofibroblast differentiation and 
CF proliferation suggests direct antifibrotic effect of αCGRP during hypertension-induced cardiac 
remodelling. This is in accordance with previous reports showing αCGRP's protective effects on various 
cells including cardiomyocytes in vitro.41 Our finding that αCGRP has, in addition to its vasodilating 
properties, direct hormonal effects on the heart at relatively low plasma concentrations is supported by the 
notion that is the stimulus and not its chronicity what determines the myocardial phenotype.8,9 Moreover,  
pregnancy, a more chronic cardiac stimulus than exercise, is associated with physiological cardiac 
hypertrophy52 and, markedly increased plasma αCGRP concentrations.53 The pregnancy-induced 
physiological cardiac hypertrophy disappears after delivery simultaneously with normalization of the 
elevated plasma CGRP concentrations.52,53 
 
It is debated whether endogenous plasma αCGRP concentrations are high enough or can reach 
sufficient levels to mediate cardioprotection under certain circumstances. Normal plasma αCGRP 
concentrations range from 10-250 pg/mL in mice54-56 and around 200 pg/mL in humans.31 After a maximal 
exercise test in man, plasma αCGRP concentrations were increased by nearly 30%.10 A recent study 
reported approximately 70% increase in plasma αCGRP concentrations after forced exercise (26 m min−1 
for 60 min) in rats43 that stimulated adipose tissue lipolysis during exercise, an effect that was inhibited by 
CGRP8-37 pretreatment. This supports our findings that exercise-induced αCGRP exerts hormonal effects. 
However, even exercise-independent plasma αCGRP appears to exert cardioprotection, especially during 
chronic hypertension because cardiac phenotype and function were worse in sedentary, vehicle-treated 
hypertensive αCGRP-/- mice and sedentary, CGRP8-37-treated WT mice compared with sedentary, 
vehicle-treated WT mice (Figures 2, 4-7). This strongly suggests that even basal plasma αCGRP 
concentrations (Online Table I), most likely due to overspill from normal peripheral neuronal activity41, are 
important for maintaining a healthy heart function in situations of cardiac stresses such as chronic 
hypertension. Moreover, the shortly peaking αCGRP concentrations might be the key explaining the 
beneficial cardiovascular effects of exercise in healthy people, hypertensive patients and those with 
impaired heart function.37 This notion is well-supported by our finding that plasma CGRP is significantly 
increased already after 7 minutes of voluntary wheel running (Figure 3D, E) and that cardioprotective 
effects of exercise are completely abolished by CGRP8-37 treatment in mice. 
 
Here, we used a mouse model of chronic hypertension (not induced by genetic modification) with 
a total of 84 days duration, which is longer than many described in the literature (median duration: 28 d, 
mean duration: 49±45 d, Online Table X). Implanting AngII-filled micro-osmotic pumps, the most common 
model used for creating systemic hypertension, is limited by the fact that in mice, only small pumps 
(maximum 4 weeks duration of drug delivery) can be used. In order to address the effects of lifestyle 
changes, e.g. increased physical activity, longer duration chronic hypertension models appear to be 
clinically more relevant. The same holds also for the fact that in clinical reality, therapy typically starts not 
simultaneously with, or just shortly after, onset of hypertension, as in many previous basic studies (Online 
Table X), but rather when the patient has lived with the problem for a considerable time. Accordingly, we 
started the treatment and exposed the mice to voluntary wheel running after 8 weeks of hypertension, and 
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sedentary lifestyle, increasing the level of physical activity is still effective in hypertensive patients.45,57 As 
we show here, these beneficial effects of exercise are independent of normalizing the elevated BP. This 
clearly reinforces the notion that patients that do not respond to pharmaceutical antihypertensive therapy or 
have signs of HF can profit from increased physical activity.37,45 The data presented here and in our previous 
work9 show that one mediator of the beneficial cardiac effects of exercise is αCGRP. Therefore, αCGRP 
analogues could be useful, especially in hypertensive patients with additional co-morbidities that are 
common in elderly patients, thus, preventing them from taking part in or strictly adhering to suggested 
exercise regimens.  
 
On the other hand, αCGRP plays a crucial role in the pathophysiology of migraine, a debilitating 
neurovascular disorder affecting about 16% of the population worldwide. Therefore, antibodies with long 
biological half-life (> 45 days) against αCGRP or its receptor have recently been approved for clinical 
use.32,58 Longtime experience with αCGRP-antagonists for migraine prophylaxis are missing. However, our 
data suggest that chronic inhibition of endogenous αCGRP signaling might induce adverse cardiovascular 
effects, especially in hypertensive individuals (that were not included in the original clinical trials for 
αCGRP antagonists).  
 
Taken together, we demonstrate here for the first time that (1) in mice, the basal, exercise-
independent plasma αCGRP is an important survival factor in hypertension, (2) additional cardioprotective 
effects of voluntary exercise, when started at the stage of stable chronic hypertension are αCGRP-
dependent, and (3) αCGRP is cardioprotective also independent of its BP normalization effects. Thus, 
endogenously-activated αCGRP maintains cardiac health and is crucial for mediating cardioprotective 
effects of exercise during persistent pressure load. In future, αCGRP agonists might, therefore, replace 
exercise in clinical conditions where patients are mobility impaired or it is contraindicated. Moreover, we 
have found that long-term αCGRP antagonism leads to life threatening cardiac impairment during chronic 
systemic hypertension that cannot be reversed by additional exercise. This warrants attention regarding the 
cardiac function in individuals who already have hypertension, or may develop hypertension later in life, 
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Figure 1. Survival and causes of death after 1K1C surgery. (A) Kaplan-Meier survival curves of WT 
and αCGRP-/- mice following 1K1C. Comparison was performed with the Mantel-Cox test. (B) Incidences 
of fatal events diagnosed by autopsy histopathology in WT and αCGRP-/- mice that were euthanized due 
to signs of kidney failure (KF) or died suddenly without signs of impaired well-being following 1K1C. 
Dilated cardiac phenotype (DCP) was observed only in αCGRP-/- mice. 1K1C: one-kidney-one-clip, AR: 
aortic rupture, PRD: presumed cardiac rhythm disturbance. 
 
Figure 2. Basic cardiac variables in chronically hypertensive WT and αCGRP-/- mice. (A) Relative 
wall thickness (RWT), and (B) heart weight to tibia length ratio (HW/TL).  Dashed lines indicate the upper 
95% confidence interval of the mean of RWT (A) or HW/TL (B) of sham-operated WT (green, n=9) and 
αCGRP-/- (black, n=9) mice. Dot color indicates hypertensive mice with increased (blue) or decreased (red) 
RWT compared with respective sham-operated mice. (C) Proportion of animals with echocardiographically 
based classification of concentric hypertrophy (CH) and dilated cardiac phenotype (DCP) in each study 
group. (D) Systolic and diastolic blood pressure did not differ significantly between different hypertension 
experimental groups though tended to be lower in mice exhibiting DCP. Means ±S.E.M., One-way 
ANOVA, Bonferroni post-hoc test of concentric hypertrophy only and applied to (D) only. sed: sedentary.  
 
Figure 3. Exercise performance and exercise-induced plasma αCGRP concentration in chronically 
hypertensive WT and αCGRP-/- mice. (A) Total distance, (B) average daily distance and (C) average 
speed run by chronically hypertensive WT and αCGRP-/- mice over 4 weeks study period. αCGRP 
treatment significantly increased voluntary wheel running activity in WT mice. Antagonist (CGRP8-37) 
treatment had no effect compared with vehicle treatment. Vehicle-treated αCGRP-/- mice run significantly 
less compared with vehicle-treated WT mice. αCGRP treatment increased running distance also in αCGRP-
/- mice. Means ±S.E.M., Kruskal-Wallis, Dunn’s post-hoc test of concentric hypertrophy only. Refer Online 
Table IV for statistics involving whole group means. Plasma αCGRP concentration immediately after 7 
minutes of voluntary wheel running in naive normotensive (D, n=6) and vehicle-treated hypertensive (E, 
n=7) WT mice. Means ±S.E.M., unpaired t-test. sed: sedentary, CH: concentric hypertrophy, DCP: dilated 
cardiac phenotype. 
  
Figure 4. Cardiomyocyte hypertrophy in chronically hypertensive WT and αCGRP-/- mice. (A) 
αCGRP deficiency or αCGRP receptor antagonism increased cardiomyocyte cross-sectional area (CSA) 
while αCGRP treatment reversed CSA. Dashed lines indicate the mean cardiomyocyte CSA of sham-
operated WT (green, n=9) and αCGRP-/- (black, n=9) mice. Data are means ±S.E.M of 75 cells in each 
group, One-way ANOVA, Bonferroni post-hoc test of concentric hypertrophy only. Refer Online Table V 
for statistics involving whole group means. (B) Representative CFTM488A-conjugated wheat germ 
agglutinin-stained (green) myocardial sections of (A). Cell nuclei in blue. sed: sedentary, CH: concentric 
hypertrophy, DCP: dilated cardiac phenotype.  
 
Figure 5. Ejection fraction (EF), and fractional shortening (FS) in chronically hypertensive WT and 
αCGRP-/- mice. Dashed lines indicate the mean of EF (A) or FS (B) of sham-operated WT (green, n=9) 
and αCGRP-/- (black, n=9) mice. In WT mice, voluntary running improved cardiac function which was 
abolished by treatment with antagonist (CGRP8-37). Whereas voluntary running alone did not significantly 
increase cardiac function in hypertensive αCGRP-/- mice, αCGRP treatment did. Additional voluntary 
running did not further improve EF and FS (αCGRP-/-, run, αCGRP vs αCGRP-/-, sed, αCGRP). Complete 
echocardiography data are shown in Online Table VI. One-way ANOVA, Bonferroni post-hoc test of 
concentric hypertrophy only. Refer Online Table VII for statistics involving whole group means. sed: 
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Figure 6. Fetal gene expression signature in chronically hypertensive WT and αCGRP-/- mice. mRNA 
expression levels (log2-transformed) of (A) myosin heavy chain-6 (Myh6), (B) myosin heavy chain-7 
(Myh7), (C) atrial natriuretic peptide (Nppa), (D) brain natriuretic peptide (Nppb), and (E) sarcoplasmic 
reticulum Ca2+ ATPase-2 (SERCA2) in cardiac tissues of sedentary and voluntarily running chronically 
hypertensive mice. Dashed lines indicate the mean expression level of respective mRNA in sham-operated 
WT (green, n=9) and αCGRP-/- (black, n=9) mice. Global αCGRP deficiency or αCGRP receptor 
antagonism reduced Myh6 and SERCA2 expression while simultaneously increasing expression of Myh7, 
Nppa and Nppb. Data are means ±SD, One-way ANOVA, Bonferroni post-hoc test of concentric 
hypertrophy only. Refer Online Table VIII for statistics involving whole group means. sed: sedentary, CH: 
concentric hypertrophy, DCP: dilated cardiac phenotype. 
 
Figure 7. Myocardial collagen expression and fibrosis in chronically hypertensive WT and αCGRP-/- 
mice. mRNA expression levels (log2-transformed) of (A) collagen type-1 α1 (Col1a1) and (B) collagen 
type-3 α1 (Col3a1), and (C) total collagen protein were reduced by voluntary running or αCGRP treatment 
in hypertensive WT mice, an effect that was inhibited by antagonist (CGRP8-37) treatment. Exercise did 
not reverse the pro-fibrotic phenotype in vehicle-treated αCGRP-/- mice. In contrast, αCGRP treatment 
considerably reduced Col1a1 and Col3a1 expression, and total collagen protein in αCGRP-/- hearts. Dashed 
lines indicate the mean expression level of respective targets in sham-operated WT (green, n=9) and 
αCGRP-/- (black, n=9) mice. Data are means ±S.E.M, One-way ANOVA, Bonferroni post-hoc test of 
concentric hypertrophy only. Refer Online Table VIII for statistics involving whole group means. These 
observations were confirmed by van Gieson’s staining as shown in panel (D). sed: sedentary. CH: 
concentric hypertrophy, DCP: dilated cardiac phenotype.  
 
Figure 8. Effect of αCGRP treatment on myofibroblast differentiation and proliferation of cardiac 
fibroblasts (CF). (A) cAMP levels in murine CF treated with either αCGRP alone or αCGRP+CGRP8-37 
for 20 min.  (B) mRNA expression levels of collagen type-1 α1 (Col1a1) and collagen type-3 α1 (Col3a1), 
and (C) collagen protein in CF treated in the presence or absence of cAMP synthesis inhibitor 2’5-DDA 
and EPAC1 inhibitor CE3F4 as indicated for 48 h (B) or 72 h (C). (D) Immunofluorescence staining of 
collagen in CF treated as indicated   for 72 h. Blue, cell nuclei. Negative control was obtained by omitting 
the primary antibody. Microphotographs represent triplicates of three independent experiments. (E) 
Proliferative capacity of CF treated in the presence or absence of 2’5-DDA and CE3F4 as indicated for 36 
h. (F) EPAC1 mRNA and protein concentrations in CF treated as indicated for 12 h (mRNA) or 24 h 
(protein). Taken together, αCGRP specifically inhibits myofibroblast differentiation and proliferation of 
CF through cAMP effector EPAC1.  Means ±S.E.M of three (A, B, C, F) or five (E) independent 


































DOI: 10.1161/CIRCRESAHA.119.315429  18 
 
Novelty and Significance 
 
What Is Known? 
 
 Exercise has cardioprotective effects in chronic hypertension. 
 
 Plasma alpha calcitonin gene-related peptide (αCGRP) concentration is increased during exercise 
due to spill over from neurons innervating working skeletal muscles and promotes physiological 
cardiomyocyte growth. 
 
 When given in vasodilatory or blood pressure normalizing dosages, αCGRP and αCGRP-analogues 
inhibit hypertension-induced heart damage.  
 
What New Information Does This Article Contribute? 
 
 Basal, plasma concentrations of endogenous αCGRP are essential for maintaining cardiac function 
in chronic sustained hypertension.  
 
 Cardioprotective effects of exercise in chronic persistent hypertension are mediated through 
endogenous αCGRP signaling. 
 
 
Regular physical activity or exercise alleviates pathological cardiac remodeling and is therefore 
recommended as a key component of cardiac rehabilitation in chronic hypertensive patients. The 
neuropeptide αCGRP has causative roles in migraine and is released by exercising skeletal muscles. It has 
positive chronotropic and inotropic effects and stimulates physiological cardiomyocyte growth. Infusion of 
αCGRP can acutely improve cardiac function in congestive heart failure and hypertension. We demonstrate 
here for the first time that basal, exercise-independent endogenous αCGRP is crucial (i) for suppressing 
pathological cardiac growth, myocardial fetal gene reactivation and interstitial fibrosis as well as (ii) for 
preserving cardiac function in chronic hypertension, independent of lowering the pathologically elevated 
blood pressure. Therefore, inhibition of endogenous αCGRP, currently approved as prophylactic migraine 
therapy, may adversely affect cardiac function in individuals who already have hypertension, or may 
develop hypertension later in life. Further, we found that the cardioprotective effects of exercise in 
hypertension are αCGRP-dependent. Hence, αCGRP antagonists may invalidate exercise recommendations 
in chronic hypertensive patients. On the other hand, αCGRP agonism may be an alternative therapeutic 
strategy to mimic cardioprotective effects of exercise in clinical conditions where patients are mobility 
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